AMENDMENTS TO THE SPECIFICATION

In the Specification:

Please replace the paragraph beginning at page 3, line 4 with the following amended paragraph:

Examples for tetrapeptides as caspase inhibitors are DEVD (SEQ ID NO: 1), Ac-DEVD-CHO (SEQ ID NO: 67), Z-Asp-CH_2-DCB, acetyl-Asp-Glu-Val-Asp-fluoromethyl-ketone (Ac-DEVD-FMK) (SEQ ID NO: 68), YVAD (SEQ ID NO: 2), acetyl-Tyr-Val-Ala-Asp-chloromethyl-ketone (Ac-YVAD-CMK) (SEQ ID NO: 69), z-DEVD-fmk (SEQ ID NO: 70), benzyloxycarbonyl-Asp(OCH_3)-Glu(OCH_3)-Val-Asp(OCH_3)--CH_2-fluoromethyl ketone (SEQ ID NO: 71) and z-IETD-fmk (SEQ ID NO: 72).

Please replace the paragraph beginning at page 4, line 11 with the following amended paragraph:

One especially preferred caspase inhibitor is Ac-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-CMK) (SEQ ID NO: 69) as component of the coating of the above mentioned medical products.

Please replace the paragraph beginning at page 5, line 24 with the following amended paragraph:

Furthermore, it is advantageous when R represents a peptide comprising the tetrapeptide His-Phe-Arg-Trp (SEQ ID NO: 74) or the tripeptides Phe-Arg-Trp or His-Phe-Arg.

Please replace the paragraph beginning at page 7, line 5 with the following amended paragraph:

Furthermore, the following compounds are preferred: R"-His-Phe-Arg-Trp-R'-Lys-X (SEQ ID NO: 75) , R"-His-Phe-Arg-Trp-R'-Lys-Pro-X' (SEQ ID NO: 76), R"-His-Phe-Arg-Trp-R'-Lys-Pro-Thr-X' (SEQ ID NO: 77), R"-His-Phe-Arg-Trp-R'-Lys-Pro-Val-X' (SEQ ID NO: 78), R"-Phe-Arg-Trp-R'-Lys-X (SEQ ID NO: 79), R"-Phe-Arg-Trp-R'-Lys-Pro-X' (SEQ ID NO: 80), R"-Phe-Arg-Trp-R'-Lys-Pro-Thr-X' SEQ ID NO: 81), R"-Phe-Arg-Trp-R'-Lys-Pro-Val-X' SEQ ID NO: 82), R"-His-Phe-Arg-R'-Lys-X SEQ ID NO: 83), R"-His-Phe-Arg-R'-Lys-Pro-X' SEQ ID NO: 84), R"-His-Phe-Arg-R'-Lys-Pro-Thr-X' (SEQ ID NO: 85), and R"-His-Phe-Arg-R'-Lys-Pro-Val-X' (SEQ ID NO: 85) wherein X' represents a hydroxyl group, an amino group, a monoalkyl or dialkylamino group, an alkoxy group, an amino acid, an oligopeptide with 1 – 8, preferably with 1 – 3 and more preferably with 1 or two amino acids and wherein R' represents an oligopeptide of 1 – 10 amino acids and R" is selected from the group comprising hydrogen, acyl group, acetyl group, an amino acid or a peptide with 1 – 60 amino acids.

Please replace the paragraph beginning at page 8, line 1 with the following amended paragraph:

One especially preferred compound of general formula R-Lys-X is SYSMEHFRWGKPV (SEQ ID NO: 64). It is also preferred if one amino acid, more preferred if 3 amino acids, still more preferred if 6 amino acids and most preferred if more than 10 amino acids have D-configuration.

Please replace the paragraph beginning at page 19, line 10 with the following amended paragraph:

The caspase inhibitor Ac-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-CMK) (SEQ ID NO: 69) was locally administered during the test period via a perfusion balloon by means of a poly-lumen catheter. Said catheter consists of an infusion connector, a catheter body and distal infusion regions comprising 4 separate lumens.

Please replace the paragraph beginning at page 20, line 21 with the following amended paragraph:

It could be demonstrated that said parts of the blood vessel which were treated with an apoptosis inhibitor (in the present case with Ac-YVAD-CMK) (SEQ ID NO: 69) showed a reduction of plaque volume to approximately 1/6, a reduction of maximum plaque area to approximately 1/3 and a reduction of the stenotisized (the area which comes into contact with the introduced stent) area to approximately 40% in comparison with the values obtained from the negative control group. 7 pigs were used for each group, the positive and the negative control group.

Please replace the Sequence Listing with the enclosed sequence listing having 86 SEQ ID NOS.